<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320979</url>
  </required_header>
  <id_info>
    <org_study_id>19/317-2101</org_study_id>
    <nct_id>NCT04320979</nct_id>
  </id_info>
  <brief_title>Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients</brief_title>
  <official_title>Postmastectomy Prophylactic Internal Mammary Nodal Irradiation for High-risk Patients With Non-metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Provincial Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tangshan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Union Hospital, Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anyang Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Dayi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fuwai Hospital of Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of internal mammary nodal irradiation on
      disease-free survival in high-risk breast cancer patients treated with mastectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients are randomized into 2 groups: chest wall and supraclavicular nodal
      +-axillary plus internal mammary nodal irradiation, and chest wall and supraclavicular nodal
      +-axillary nodal irradiation. The prescription dose is 50 Gy in 25 fractions over 5 weeks or
      43.5Gy in 15 fractions over 3 weeks.

      During and after radiotherapy, the patients are followed and the efficacy and toxicities of
      radiotherapy are evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>failure: relapse of ipsilateral chest wall, axilla, supraclavicular and internal mammary nodal or distant metastasis or contralateral invasive breast cancer or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>the incidence of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative internal mammary nodal recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>ipsilateral internal mammary nodal relapse during follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative locoregional recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>ipsilateral chest wall, axilla, supraclavicular and internal mammary nodal relapse during follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis</measure>
    <time_frame>5 years</time_frame>
    <description>the incidence of first relapse beyond locoregional region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contralateral invasive breast cancer or other malignant tumors</measure>
    <time_frame>5 years</time_frame>
    <description>the incidence of contralateral invasive breast cancer or other malignant tumors developed after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major cardiovascular events</measure>
    <time_frame>5 years</time_frame>
    <description>the incidence of death due to coronary heart disease or other heart disease, development of myocardial infarction, coronary recanalization, or hospitalization for a major cardiovascular events (such as heart failure, valvular disease, arrhythmia, unstable angina, or other major cardiovascular event).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>graded according to radiation therapy oncology group (RTOG) radiation injury criteria and National Cancer Institute CTCAE version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>questionaire analysis with European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-BR23 scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>internal mammary nodal irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chest wall and supraclavicular nodal+-axillary plus internal mammary nodal irradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no-internal mammary nodal irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ipsilateral chest wall and supraclavicular +-axillary nodal irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>internal mammary nodal irradiation</intervention_name>
    <description>chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).</description>
    <arm_group_label>internal mammary nodal irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>no internal mammary nodal irradiation</intervention_name>
    <description>chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).</description>
    <arm_group_label>no-internal mammary nodal irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group Performance Status Scale 0-2

          -  Histologically confirmed invasive breast cancer

          -  Underwent total mastectomy and axillary dissection(10 or more axillary lymph nodes
             detected) and negative margins

          -  Patients who had ≥4 positive axillary lymph nodes; or 1-3positive axillary lymph nodes
             and T3-4; or 1-3positive axillary lymph nodes and T1-2, and score≥3 based on the
             following high risk factors: age≤40 years(score 1), primary tumor in the inner
             quadrant (score 1), 2-3 positive axillary lymph nodes (score 1), positive vascular
             invasion (score 1), re-staged based on eighth Cancer Staging System staging
             system(IB-IIA score 1， IIB-IIIA score 2); or ypN+ after neoadjuvant chemotherapy

          -  No supraclavicular or internal mammary nodes metastases based on images before system
             therapy

          -  No distant metastases

          -  Could tolerate radiotherapy

          -  Treated with chemotherapy (anthracycline and/or taxane-based combined chemotherapy, ≥3
             cycles)

          -  Anticipated to receive endocrine therapy for 5 years if indicated

          -  Anticipated to receive anti-HER2 therapy for 1 years if indicated

          -  LVEF≥50% based on echocardiogram

          -  Willing to follow up

          -  Written,informed consent

        Exclusion Criteria:

          -  Simultaneous bilateral breast cancer

          -  Sentinel lymph node biopsy only without axillary dissection

          -  Had received internal mammary node dissection

          -  No imaging assessment of the internal mammary nodal before system therapy

          -  One-stage breast reconstruction

          -  Severe cardiac insufficiency; myocardial infarction or uncorrected unstable arrhythmia
             or uncorrected unstable angina in the last 3 months; pericardial disease

          -  Had history of chest wall or supraclavicular radiotherapy

          -  Had simultaneous or previous secondary malignancies, except for non-malignant melanoma
             skin cancer, papillary thyroid / follicular carcinoma, cervical carcinoma in situ,
             contralateral non-invasive breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shu-lian Wang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ye-xiong Li, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shu-lian Wang, M.D</last_name>
    <phone>8610-87788803</phone>
    <email>wsl20040118@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8610-87788803</phone>
      <email>wsl20040118@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Shu-lian Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shu lian Wang</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>breast neoplasm</keyword>
  <keyword>mastectomy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>internal mammary node</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

